EICHOR
● Active Not Recruiting
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Condition: Hidradenitis Suppurativa · Sponsor: AbbVie
About this study
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe HS . Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 of the study, participants will placed in 1 of 2 groups called treatment arms. There is a 1 in 2 chance that participants will be assigned to placebo. Around 1280 adult and adolescent participants with moderate to severe HS will be enrolled in the study at approximately 275 sites world wide. During Period 2, participants that were part of the lutikizumab treatment arm in Period 1 will be re-randomized to 1 of 2 lutikizumab treatment arms. Participants that were part of the Placebo arm in Period 1 will start Period 2 with an initiation of lutikizumab followed by a re-randomization to 1 of 2 lutikizumab treatment arms. In Period 1, participants will receive subcutaneous injections of lutikizumab or placebo every week for 16 weeks. In Period 2, participants that were randomized to lutikizumab in Period 1 will receive subcutaneous injections of lutikizumab every week or every other week for 36-weeks. Participants that were randomized to the placebo arm in Period 1 will receive subcutaneous…
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (279)
| Cahaba Dermatology & Skin Health Center /ID# 263795 | Birmingham, Alabama, United States | — |
| Medical Dermatology Specialists /ID# 263394 | Phoenix, Arizona, United States | — |
| Banner University Medicine Dermatology /ID# 263557 | Tucson, Arizona, United States | — |
| Dermatology Trial Associates /ID# 264587 | Bryant, Arkansas, United States | — |
| Arkansas Research Trials /ID# 263901 | North Little Rock, Arkansas, United States | — |
| Private Practice - Dr. Tooraj Raoof /ID# 263756 | Encino, California, United States | — |
| Dermatology Research Associates - Los Angeles /ID# 263765 | Los Angeles, California, United States | — |
| Stanford University School of Medicine - Redwood City /ID# 263711 | Redwood City, California, United States | — |
| Norcal Clinical Research /ID# 279008 | Rocklin, California, United States | — |
| Integrative Skin Science and Research /ID# 264600 | Sacramento, California, United States | — |
| Clinical Trials Research Institute /ID# 263743 | Thousand Oaks, California, United States | — |
| Yale University School of Medicine /ID# 263695 | New Haven, Connecticut, United States | — |
+ 267 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06468228